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Abstract
Background. a-Fetoprotein (AFP) has been used as a marker for hepatocellular carcinoma (HCC). However, AFP levels are
often high in patients with chronic hepatitis or cirrhosis. Protein-induced vitamin K absence or antagonist II (PIVKA-II) is
more sensitive for the diagnosis of HCC and prediction of patient survival. Changes in these markers after treatment may
reflect treatment curability and patient outcome. Methods. We conducted a retrospective analysis of prognosis of 63 HCC
patients with high preoperative levels of AFP and PIVKA-II who underwent hepatectomy and examined the relationship
between postoperative changes in both markers at 1 month and patient survival. Subjects were divided into three groups
according to changes in these tumour markers after hepatectomy: normalization (N) group, decreased but still above the
normal level (D) group and unchanged (U) group. Results. There were no significant differences in the numbers of patients
who developed tumour recurrence between changes in AFP and PIVKA-II. Survival analysis showed no significant
differences in tumour-free and overall survivals between groups with respect to AFP level. The PIVKA-II-N group showed
significantly better tumour-free and overall survival compared with the D and U groups (pB/0.01). Multivariate analysis
that included other prognostic factors identified changes in PIVKA-II level as a significant and independent prognostic
factor associated with overall survival. Discussion. Although changes in AFP did not correlate with patient prognosis,
normalization of PIVKA-II was significantly associated with good patient survival after hepatectomy. Normalization of
PIVKA-II after hepatectomy reflected the efficacy of treatment and is a suitable predictor of prognosis in HCC patients.
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Introduction
Sensitive tumour markers are useful for accurate
diagnosis of solid tumours. a-Fetoprotein (AFP) has
been used as a marker for hepatocellular carcinoma
(HCC) [1/4]. However, AFP levels are often high in
patients with chronic hepatitis or cirrhosis [5], there-
fore it is difficult to accurately evaluate tumour
aggressiveness. Protein induced by vitamin K absence
or antagonist II (PIVKA-II) is more specific for the
diagnosis and evaluation of tumour aggressiveness
and patient prognosis compared with AFP [5/7]. In
patients with resectable HCC, our group and other
investigators reported that preoperative PIVKA-II was
also a useful marker for predicting intrahepatic
spread, tumour recurrence and patient prognosis,
while AFP was not closely related to clinical outcome
[8/11].
We hypothesized that PIVKA-II and other sensitive
tumour markers for HCC would return to normal
levels immediately after the complete resection of
HCC, and that such normalization would reflect
improvement of patient prognosis. To test our hy-
pothesis, we selectively examined in the present study
63 patients with HCC who had high AFP and
PIVKA-II levels before hepatic resection. We evalu-
ated the relationship between changes in both markers
after hepatectomy and patient survival. Based on our
results, we also assessed the usefulness of these
tumour markers post-hepatectomy for the evaluation
of treatment efficacy.
Materials and methods
Data were collected from 94 patients with HCC
during surgery on patients who were admitted to the
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between 1996 and September 2003. Sixty-three of 94
patients (65%) with preoperatively high AFP and
PIVKA-II levels were selected in the present study.
Patients with remnant tumour after hepatectomy were
excluded from this study. The mean age of the
patients at the time of surgery was 649/8 years (range
45/81 years), and they comprised 55 males and 8
females. The background liver abnormalities included
chronic viral hepatitis in 37 (58%) patients, cirrhosis
in 24 (38%) and normal liver in 2 (4%), associated
with hepatitis virus B (n/27), hepatitis virus C (n/
35), or both hepatitis B and C (n/1). According to
the Child-Pugh classification, 60 patients were classi-
fied as A and 3 as B. The pathological tumour node
metastasis (TNM) stage of HCC according to the
Liver Cancer Study Group of Japan [12] was stage I in
2 (3%), stage II in 29 (46%), stage III in 26 (41%)
and stage IVA in 6 (10%). Prior to surgery for HCC,
three patients were treated with chemoembolization,
although such treatment failed to completely control
the growth of the tumours. After surgery, none of the
patients received adjuvant chemotherapy. The opera-
tive procedures included resection segments 2/4 (n/
11), resection segments 1/4 (n/1), resection seg-
ments 5/8 (n/12), resection segments 4/8 (n/1),
resection segments 5, 8 (n/4), resection segments 7,
8 (n/6), resection segments 5, 6 (n/4), resection
segments 6, 7 (n/7), resection segments 2, 3 (n/3),
resection segment 2 (n/1), resection segment 4
(n/2), resection segment 5 (n/1), resection seg-
ment 6 (n/3), resection segment 7 (n/3) and
resection segment 8 (n/4) [13]. All hepatic tumours
were completely resected without macroscopic expo-
sure of the remaining liver to the amputated section.
After checking at 1 month post-hepatectomy, the
patients were followed up by measuring serum levels
of AFP and PIVKA-II every 3 months, and enhanced
computed tomography (CT) of the liver was carried
out every 6 months for at least the first 5 years after
hepatectomy to rule out tumour recurrence.
The minimum follow-up period after hepatic resec-
tion of HCC was 6 months. Two of 63 (3.1%)
patients who survived were lost to follow-up and their
data were censored at the last date that they were
known to be alive. Of the 43 (61%) patients who
developed tumour recurrence after hepatectomy (in
liver, n/42 and bone, n/1), 20 were treated with
chemoembolization, 11 received ablation therapy, 1
underwent re-resection, and 11 patients received no
additional therapies. For the whole group, 27 (43%)
patients died of cancer and none died by other
diseases in the present study. The study design was
approved by the Ethics Review Board of NUGSBS
including collection of data from the NUGSBS
database, which were also provided by the associated
hospitals described above.
In the early morning, a 4-ml peripheral blood
sample was collected from each patient before and
1 month after hepatectomy. The sample was then
centrifuged at 3000 rpm (1000 g) for 10 minutes.
PIVKA-II was assayed by an enzyme-linked immu-
noassay using Eitest† PIVKA-II (Sanko Junyaku Co.,
Tokyo, Japan). The normal value of AFP in our
hospital is B/20 ng/ml. The normal value of PIVKA-II
has been determined to be B/40 mAU/ml [11].
Elevated levels of AFP and PIVKA-II were defined
as those exceeding the above levels. In the present
study, the pre-hepatectomy levels of AFP and PIVKA-
II of all 63 patients were higher than the normal
ranges. Patients were divided into three groups based
on changes in these markers after hepatectomy as
follows: normalization of these markers (i.e. return to
within the normal range, the N group), marker levels
decreased relative to preoperative level but were still
higher than the normal ranges (D group), and tumour
marker did not change (U group).
Distribution of time to treatment since 1 January
1990 was compared between groups by the Wilcoxon
rank-sum test. The disease-free interval and overall
survival were calculated using the Kaplan-Meier
method, and differences between groups were tested
for significance using the log-rank test. A two-tailed p
value of B/0.05 was considered significant. Statistical
analyses were performed using the SAS software
(Statistical Analysis System Inc., Cary, NC, USA).
Results
High AFP level was observed in 67 patients and high
PIVKA-II level was observed in 65 patients. The
mean survival period in HCC patients with a normal
AFP level (2298 days) was significantly greater than
that in patients with a higher AFP level exceeding
20 ng/ml (1350 days) (pB/0.01). The 1-, 3- and
5-year survival rates in HCC patients with a normal
AFP level were 93%, 83% and 70% and those in
patients with a higher AFP level were 82%, 56% and
47%, respectively. The overall survival in patients with
a normal AFP level was significantly greater than that
in patients with a higher AFP level. With respect to
PIVKA-II, the mean survival period in HCC patients
with a normal PIVKA-II level (2378 days) was
significantly greater than that in patients with a higher
PIVKA-II level exceeding 40 mAU/ml (1540 days)
(pB/0.01). The 1-, 3- and 5-year survival rates in
HCC patients with normal PIVKA-II level were 97%,
86% and 78% and those in patients with higher
PIVKA-II level were 85%, 62% and 51%, respec-
tively. The overall survival in patients with a normal
PIVKA-II level was significantly greater than that in
patients with a higher PIVKA-II.
With regard to the AFP level, 42 patients were
classified as the N group, 13 as the D group and 8 as
the U group. With respect to the PIVKA-II level, 49
patients classified as the N group, 11 as the D group
and 3 as the U group. The 25th, 50th and 75th sample
percentiles of the time to treatment according to AFP
level was not significantly different between groups
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(2.4 years, 4.9 years, 6.1 years for the N group; 2.9,
3.7, 5.4 for the D group; and 1.9, 4.0, 6.0 for the U
group). Similarly, the 25th, 50th and 75th sample
percentiles of the time to treatment according to
PIKA-II level were not significantly different between
groups (2.8, 4.0, 5.9 for the N group; 2.5, 4.0, 5.2 for
the D group; and 1.8, 2.5, 6.1 for the U group).
The numbers of patients who developed tumour
recurrence postoperatively according to AFP level
were 26 (62%) patients of the N group, 10 (77%) of
the D group and 7 (88%) of the U group. The
numbers of patients who developed tumour recur-
rence postoperatively according to PIVKA-II level
were 30 (48%) patients of the N group, 10 (91%) of
the D group and 3 (100%) of the U group. There were
no significant differences in these distributions in these
groups with respect to changes in AFP and PIVKA-II.
We also examined the relationship between changes
in tumour markers and mortality rate. The numbers
of patients who died postoperatively were 11 (27%)
patients of the AFP-N group, 8 (62%) of the AFP-D
group and 8 (100%) of the AFP-U group, 16 (33%)
patients of the PIVKA-II-N group, 9 (82%) of the
PIVKA-II-D group and 2 (67%) of the PIVKA-II-U
group. There were no significant differences in these
distributions in these groups with regard to changes in
AFP and PIVKA-II.
Tumour-free survival of patients in the AFP-N
group tended to be better than those of the AFP-D
and AFP-U groups, although the difference was not
significant (Figure 1A). The difference in overall
survival between N, D and U groups was not
significant (Figure 1B). The tumour-free and overall
survivals of the PIVKA-II-N group were significantly
better than those of the PIVKA-II-D and PIVKA-II-U
groups (Figure 2A and B). Table I shows the sig-
nificant prognostic factors, including changes in AFP
and PIVKA-II levels after hepatectomy, associated
with tumour-free and overall survival after hepatect-
omy, identified by the univariate analysis in the present
series. Multivariate analysis showed that although the
number and size of tumour, and long-term ascites after
hepatectomy correlated significantly with tumour-free
survival, changes in both tumour markers were not
significant factors. On the other hand, the surgical
margin of the resected liver and changes in PIVKA-II
levels were significantly associated with overall survival
after hepatectomy.
Discussion
At present, more specific HCC markers, such as
PIVKA-II or the percentage of lens culinaris aggluti-
nin A-reactive fraction of AFP (AFP L3 fraction)p=0.066
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Figure 1. Relationship between postoperative AFP level and patient
disease-free (A) and overall (B) survival after hepatectomy. Solid
line/normalization group (N group, n/42); large dotted line/D
group--postoperative AFP level was less than the preoperative value
but still higher than normal (n/13); small dotted line/unchanged
group (U group, n/8).
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Figure 2. Relationship between postoperative PIVKA-II level and
patient disease-free (A) and overall (B) survival after hepatectomy.
Solid line/N group (n/49); large dotted line/D group (n/11);
small dotted line/U group (n/3).
Postoperative changes in PIVKA-II and prognosis 139
[6/8,14,15], relative to AFP level, are usually used
for evaluation of HCC aggressiveness. High values of
these markers reflect patient prognosis after any
treatment modality [8/11,14/17]. Using multivariate
analysis, we previously showed that although the
prognosis of HCC patients is influenced by the
complex of hepatic function, tumour-related factors
and treatment-related factors [18/20], HCC staging
including PIVKA-II level is an independent prognos-
tic marker in HCC patients who undergo hepatect-
omy [21]. Monitoring of PIVKA-II is useful for
predicting tumour recurrence after hepatic resection
for HCC at an earlier period than AFP level [22,23].
PIVKA-II and AFP may decrease after effective
treatment of HCC. Therefore, in the present study
we focused on changes in these markers at an early
(i.e. 1 month) postoperative time point.
In the present study, HCC patients with preopera-
tively normal AFP/PIVKA-II levels were not included
in the present study because changes in these markers
could not be evaluated and prognosis of such patients
was better [1/4,8/11,21/23]. In the present study, in
fact, HCC patients with a normal AFP or PIVKA-II
level had a better prognosis than patients with a higher
level, respectively. Therefore, we examined HCC
patients with high preoperative levels of both AFP
and PIVKA-II and all patients underwent macrosco-
pically complete resection. These tumour markers
decreased markedly during the 1-month postoperative
period in about 90% of the patients. However, the
number of patients who showed postoperative normal-
ization of PIVKA-II level was more than that of AFP
level. A high level of AFP after hepatectomy might
reflect persistent activity of chronic hepatitis [5]. In the
present study, patients who showed normalization of
PIVKA-II had a good prognosis, although the pre-
sence of a high preoperative level of PIVKA-II is
known to correlate with poor prognosis [8/11]. On
the other hand, patients in the D group (in whom
PIVKA-II decreased postoperatively, but the level was
still above normal) and U group (no change in the
marker level post-operatively) showed poor prognosis
after surgery. Kanazumi et al. [24] reported that
serum PIVKA-II level was decreased within 2 weeks
after effective operation and, therefore, a PIVKA-II
level higher than than normal range might reflect
remnant HCC. In the present series, no additional
treatment was provided based only the serum level of
tumour markers at 1 month after hepatectomy in the
D or U groups. Currently, there are no standardized
rules for the selection of specific treatment modality
for recurrent tumour detected by imaging studies, e.g.
enhanced CT. However, taking into consideration the
present results, we suggest that in patients with high
PIVKA-II level after hepatectomy, adjuvant therapy
such as chemotherapy should be provided to control
invisible remnant HCC cells, which could lead to
better patient survival.T
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AFP level after hepatectomy did not correlate with
patient survival. Recent studies showed that the per-
centage of AFP L3 fraction was a better specific marker
for HCC than AFP level [14/17]. It is necessary to
examine this marker before and after hepatectomy for
better assessment of patient prognosis in the next step
of our study. If this marker is useful, similar to PIVKA-
II, the combination of these tumour markers may be
useful for evaluation of tumour aggressiveness.
In summary, we conducted a retrospective analysis
of the prognosis of 63 HCC patients who underwent
hepatic resection, including examination of the rela-
tionship between changes in AFP and PIVKA-II after
hepatectomy and patient survival. Compared to
change in AFP, normalization of PIVKA-II level was
more significantly associated with good patient survi-
val after hepatectomy by univariate and multivariate
analyses. Normalization of PIVKA-II level after he-
patectomy reflected the efficacy of the treatment and
is a suitable predictor of prognosis in HCC patients.
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